Blog

Posts Tagged ‘drug stocks’

My fifth pick in my Special Report “10 Stocks to Beat Amazon” is a water stock, Danaher (DHR)

My fifth pick in my Special Report "10 Stocks to Beat Amazon" is a water stock, Danaher (DHR.) Danaher's trailing average annual returns don't look to be in Amazon's (AMZN) class--if all you do is look at the long-term 15-year period. Over a 15-year period Amazon's average annual return is 33.93%. Danaher's is just 14.48%. […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

4th pick for Special Report 10 Stocks to Beat Amazon–SGEN

My fourth pick in my Special Report "10 Stocks to Beat Amazon" is a biotech, Seattle Genetics (SGEN). Biotech companies spend years developing their first successful drug. And then spend more years turning that first drug into a pipeline of drugs and expanded labels. The risk, of course, is that the drug development efforts won't […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months

I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some point--when, only the world's central bankers […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Trump administration picks five coronavirus vaccine efforts to receive big government funding

The Trump administration has identified five companies that will get major government funding for the development of a coronavirus vaccine under Operation Warp Speed, the New York Times reported yesterday. The White House is expected to officially announce the names of the five companies on the short list sometime in the next few weeks. The […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Selling Intrexon (now Precigen) after 293% gain today

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

AbbVie continues its run–picks up momentum from Allergan results

Shares of AbbVie (ABBV) tacked on another 1.32% today to a close at $96 continuing a run that began back on January 31 at $81.02. The trend picked up momentum on February 7 after the company reported fourth quarter earnings with better than expected sales for its blockbuster Humira drug that has picked up competition […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Buying AbbVie today for my Dividend Portfolio with its 5.62% yield

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar's application for its new non-addictive opioid NKTR-181. The thinking--my thinking--was that the committee had structured the vote so that the most likely outcome was a narrow approval of the drug candidate that required further clinical trials by Nektar. Nope. […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Merck continues to ride cancer drug Keytruda higher

 Shares of Merck (MRK) closed up 3.50% today, October 29, after the company reported better than expected third quarter earnings. On a Non-GAAP basis earnings of $1.51 a share beat the Wall Street consensus by 27 cents a share. Revenue of $12.4 billion fell 6.7% year over year but beat analysts projections of $11.64 billion. […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Selling Pfizer out of my Dividend Portfolio tomorrow on Dem’s proposed drug-pricing bill

Why introduce legislation that will dead on arrival in the Republican controlled Senate? Because House Speaker Nancy Pelosi and other Democrats know that controlling drug prices is extremely popular with voters. And a proposal that is a serious effort to lower drug prices is a hammer that can be used over and over again to […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.